101 related articles for article (PubMed ID: 9011736)
1. [National consensus on hyperandrogenemia].
Aganović I; Alac M; Cabrijan T; Grizelj V; Korsić M; Misjak-Vitez M; Reiner Z; Suchanek E; Simunić V; Zjacić-Rotkvić V
Lijec Vjesn; 1996 Sep; 118(9):189-90. PubMed ID: 9011736
[TBL] [Abstract][Full Text] [Related]
2. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome.
Amato MC; Galluzzo A; Finocchiaro S; Criscimanna A; Giordano C
Clin Endocrinol (Oxf); 2008 Jul; 69(1):52-60. PubMed ID: 18034780
[TBL] [Abstract][Full Text] [Related]
3. [Early metabolic abnormalities--insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome].
Otto-Buczkowska E; Jarosz-Chobot P; Deja G
Przegl Lek; 2006; 63(4):234-8. PubMed ID: 17080748
[TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
5. Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: implications for identifying hyperandrogenaemia.
Cho LW; Kilpatrick ES; Jayagopal V; Diver MJ; Atkin SL
Clin Endocrinol (Oxf); 2008 Mar; 68(3):390-4. PubMed ID: 17888022
[TBL] [Abstract][Full Text] [Related]
6. Secondary forms of polycystic ovary syndrome.
Kaltsas GA; Isidori AM; Besser GM; Grossman AB
Trends Endocrinol Metab; 2004 Jul; 15(5):204-10. PubMed ID: 15223049
[TBL] [Abstract][Full Text] [Related]
7. Polycystic ovary syndrome and type 2 diabetes mellitus.
De Leo V; Musacchio MC; Morgante G; La Marca A; Petraglia F
Minerva Ginecol; 2004 Feb; 56(1):53-62. PubMed ID: 14973410
[TBL] [Abstract][Full Text] [Related]
8. Endocrinological markers for assessing hyperandrogenemia in women classified as having polycystic ovary syndrome (PCOS) according to the revised 2003 diagnostic criteria.
Mueller A; Dittrich R; Binder H; Hoffmann I; Beckmann MW; Cupisti S
Eur J Med Res; 2006 Dec; 11(12):540-4. PubMed ID: 17182367
[TBL] [Abstract][Full Text] [Related]
9. [Polycystic ovary syndrome].
Dewailly D
J Gynecol Obstet Biol Reprod (Paris); 2000 May; 29(3):298-301. PubMed ID: 10804375
[TBL] [Abstract][Full Text] [Related]
10. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
11. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
[TBL] [Abstract][Full Text] [Related]
12. Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome?
Corbould A
Diabetes Metab Res Rev; 2008 Oct; 24(7):520-32. PubMed ID: 18615851
[TBL] [Abstract][Full Text] [Related]
13. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
14. Polycystic ovary syndrome in the Indian Subcontinent.
Allahbadia GN; Merchant R
Semin Reprod Med; 2008 Jan; 26(1):22-34. PubMed ID: 18181079
[TBL] [Abstract][Full Text] [Related]
15. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria.
Kauffman RP; Baker TE; Baker VM; DiMarino P; Castracane VD
Am J Obstet Gynecol; 2008 Jun; 198(6):670.e1-7; discussion 670.e7-10. PubMed ID: 18355776
[TBL] [Abstract][Full Text] [Related]
16. Is prostate-specific antigen a potential new marker of androgen excess in polycystic ovary syndrome?
Vural B; Ozkan S; Bodur H
J Obstet Gynaecol Res; 2007 Apr; 33(2):166-73. PubMed ID: 17441890
[TBL] [Abstract][Full Text] [Related]
17. Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications.
Nardo LG; Patchava S; Laing I
Panminerva Med; 2008 Dec; 50(4):267-78. PubMed ID: 19078868
[TBL] [Abstract][Full Text] [Related]
18. [Diagnosis and treatment of polycystic ovary syndrome].
Gandar R; Spizzo M; Collin D
J Gynecol Obstet Biol Reprod (Paris); 1999 Oct; 28(6):510-8. PubMed ID: 10598343
[TBL] [Abstract][Full Text] [Related]
19. Androgens in polycystic ovary syndrome: the role of exercise and diet.
Giallauria F; Palomba S; Vigorito C; Tafuri MG; Colao A; Lombardi G; Orio F
Semin Reprod Med; 2009 Jul; 27(4):306-15. PubMed ID: 19530064
[TBL] [Abstract][Full Text] [Related]
20. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
